In the 10 years since our previous International Union of Basic and Clinical Pharmacology
report on the nomenclature and classification of adenosine receptors, no developments …

Medicinal chemical approaches have been applied to all four of the adenosine receptor
(AR) subtypes (A1, A2A, A2B, and A3) to create selective agonists and antagonists for each …

The adenosine A2A receptor is a G-protein-coupled receptor (GPCR) that has been
extensively studied during the past few decades because it offers numerous possibilities for …

Alchemical free energy simulations have long been utilized to predict free energy changes
for binding affinity and solubility of small molecules. However, while the theoretical …

Neurotransmitters other than dopamine, such as norepinephrine, 5-hydroxytryptamine,
glutamate, adenosine and acetylcholine, are involved in Parkinson's disease (PD) and …

The impressive ability of palladium to assemble CC bonds between appropriately
functionalized substrates has allowed synthetic organic chemists to perform transformations …

The purine nucleoside adenosine is consensually identified as a major local regulator of
tissue function especially when energy supply fails to meet cellular energy demand. Due to …

Several selective antagonists for adenosine A2A receptors (A2AR) are currently under
evaluation in clinical trials (phases I to III) to treat Parkinson's disease, and they will probably …

The rapid growth of structural information for G-protein-coupled receptors (GPCRs) has led
to a greater understanding of their structure, function, selectivity, and ligand binding …

A2A adenosine receptor antagonists are currently under investigation as potential
therapeutic agents for Parkinson's disease (PD). However, the molecular mechanisms …